Literature DB >> 9016274

Dopamine reuptake site densities in patients with social phobia.

J Tiihonen1, J Kuikka, K Bergström, U Lepola, H Koponen, E Leinonen.   

Abstract

OBJECTIVE: It has been suggested that social phobia is associated with dysfunction of the noradrenergic and dopaminergic systems, but there are no published anatomic data on the monoaminergic abnormalities found in the brains of phobic patients. The authors studied the density of dopamine reuptake sites in patients with social phobia.
METHOD: The study included 11 patients with social phobia and 28 healthy comparison subjects, 11 of whom were age- and gender-matched to the patients for the analyses. Measurement of the density of dopamine reuptake sites was performed by using a 123I-labeled cocaine analogue, [123I]beta-CIT, with single photon emission computed tomography (SPECT).
RESULTS: Blind quantitative analysis revealed that striatal dopamine reuptake site densities were markedly lower in the patients with social phobia than in the age- and gender-matched comparison subjects.
CONCLUSIONS: The results indicate that social phobia may be associated with a dysfunction of the striatal dopaminergic system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9016274     DOI: 10.1176/ajp.154.2.239

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  36 in total

Review 1.  Unmasking social anxiety disorder.

Authors:  M B Stein; J M Gorman
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

Review 2.  Toward an integrative understanding of social phobia.

Authors:  D Li; P Chokka; P Tibbo
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

3.  Motor cortex excitability correlates with novelty seeking in social anxiety: a transcranial magnetic stimulation investigation.

Authors:  Stefano Pallanti; Alessandra Borgheresi; Ilenia Pampaloni; Fabio Giovannelli; Silvia Bernardi; Andrea Cantisani; Gaetano Zaccara; Massimo Cincotta
Journal:  J Neurol       Date:  2010-03-30       Impact factor: 4.849

4.  A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonist.

Authors:  Kevin J Black; Tamara Hershey; Jonathan M Koller; Tom O Videen; Mark A Mintun; Joseph L Price; Joel S Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-13       Impact factor: 11.205

5.  Reduced dopamine receptors and transporters but not synthesis capacity in normal aging adults: a meta-analysis.

Authors:  Teresa M Karrer; Anika K Josef; Rui Mata; Evan D Morris; Gregory R Samanez-Larkin
Journal:  Neurobiol Aging       Date:  2017-05-12       Impact factor: 4.673

6.  Striatal functional alteration during incentive anticipation in pediatric anxiety disorders.

Authors:  Amanda E Guyer; Victoria R Choate; Allison Detloff; Brenda Benson; Eric E Nelson; Koraly Perez-Edgar; Nathan A Fox; Daniel S Pine; Monique Ernst
Journal:  Am J Psychiatry       Date:  2012-02       Impact factor: 18.112

Review 7.  Pain, affective symptoms, and cognitive deficits in patients with cerebral dopamine dysfunction.

Authors:  Johanna M Jarcho; Emeran A Mayer; Ziyue Karen Jiang; Natasha A Feier; Edythe D London
Journal:  Pain       Date:  2012-03-03       Impact factor: 6.961

8.  Dopaminergic Mechanisms Underlying Normal Variation in Trait Anxiety.

Authors:  Anne S Berry; Robert L White; Daniella J Furman; Jenna R Naskolnakorn; Vyoma D Shah; Mark D'Esposito; William J Jagust
Journal:  J Neurosci       Date:  2019-02-08       Impact factor: 6.167

9.  Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder.

Authors:  Franklin R Schneier; Anissa Abi-Dargham; Diana Martinez; Mark Slifstein; Dah-Ren Hwang; Michael R Liebowitz; Marc Laruelle
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

Review 10.  The neurocircuitry of fear, stress, and anxiety disorders.

Authors:  Lisa M Shin; Israel Liberzon
Journal:  Neuropsychopharmacology       Date:  2010-01       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.